Reference
- Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein—Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002;84:175–201.
- Lucas KG, Burton RL, Zimmerman SE et al. Semi-quantitative Epstein—Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998;91:3654–61.
- Papadopoulos EB, Ladanyi M, Emanuel D et al Infusions of donor leukocytes to treat Epstein—Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl .7 Med 1994;330:1185–91.
- Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl 7 Med 1994; 331:679–80.
- Rooney CM, Smith CA, Ng C et al. Use of gene-modified virus-specific T lymphocytes to control Epstein—Barr virus-related lymphoproliferation. Lancet 1995;345:9–13,
- Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein—Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551–5.
- Rooney CM, Smith CA, Ng CYC et al. Infiision of cytotoxic T cells for the prevention and treatment of Epstein—Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549–55.
- Gottschalk S, Ng CYC, Smith CA et al. An Epstein—Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001;97:835–43.
- Bollard C, Onishi H, Huls M et al. Long-term follow-up of patients who received EBV-specific CTLs for the preven-tion or treatment of EBV-associated lymphoproliferative disease [abstract]. Biol Blood Marrow Transplant 2001;7:61.
- Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein—Barr virus-associated diseases [in process citation]. Annu Rev Microbiol 2000;54:19–48.
- Liu Z, Wilson JM, Jones MC et al. Addition of B cell depletion of donor marrow with anti-CD20 antibody to a T cell depletion regimen for prevention of EBV lymphoma after bone marrow transplant [abstract]. Blood 1999;94:638a.
- Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal anti-body (rituximab) for therapy of Epstein—Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502–5.